Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Dagens aktienyheder 09/02-2026: Bioporto

By Michael FriisHead of Equities
BioPorto

BioPorto kan her til morgen offentliggøre, at de har udnævnt Klaus Juhl Wulff som ny EVP og CFO med tiltrædelse senest 1. maj 2026. Klaus Juhl Wulff indtræder samtidig i den øverste ledelse. Han kommer fra en stilling som CFO i AquaPorin og har mere end 20 års erfaring inden for finans, drift, M&A og kapitalmarkeder. Som en del af sit ansvarsområde vil han få det strategiske ansvar for supply chain med henblik på at understøtte den forventede høje vækst fremadrettet. Ledelsen. CFO skifte var et af de spørgsmål der dukkede op på vores event i fredags, hvor vækstudsigterne for 2026 og fremadrettet ovenpå første guidance blev drøftet. Se eventet her: https://www.inderes.dk/videos/bioporto-praesentation-af-forelobige-2025-resultater-samt-2026-guidance

Disclaimer: HC Andersen Capital modtager betaling fra de nævnte selskaber for en digital IR abonnementsaftale. /Michael Friis d. 09/02/2026 kl. 08:51.

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel. It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.